Phenol Sulfotransferase Sult1a1*2 Allele and Enhanced Risk of Upper Urinary Tract Urothelial Cell Carcinoma

Rouprêt, Morgan; Cancel‐Tassin, Géraldine; Comperat, E.; Fromont, G.; Sibony, Mathilde; Molinié, Vincent; Allory, Yves; Triau, Stéphane; Taille, A. De La; Chartier-Kastler, E.; Mo, Bitker; Richard, Frédéric; Hamdy, Freddie C.; Cussenot, Olivier

doi:10.1016/s1569-9056(08)60878-7

Cited by 9 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Obvious heterogeneity between studies was observed when we included all eligible studies. Consistently, through meta-regression analysis and creation of a Galbraith plot, we observed that the study of Roupret et al (18), which was the only study that included UTUC patients as case group, was the main source of heterogeneity. The degree of heterogeneity significantly decreased after this study was excluded.…”

Section: Discussionsupporting

confidence: 63%

See 1 more Smart Citation

Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma

Liu

Huang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

Abstract. Sulfotransferase isoform 1A1 (SULT1A1) is a member of the sulfotransferase family that plays an important role in the biotransformation of numerous carcinogenic and mutagenic compounds through sulfation. A number of case-control studies were conducted to investigate the association between the Arg213His polymorphism in SULT1A1 and the risk of urothelial carcinoma (UC) in humans. However, the results were inconsistent. A meta-analysis based on 10 case-control studies was performed to address this issue. Crude odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to estimate the strength of this association. Between-study heterogeneity was assessed with the Chi-square-based Q test. Overall, a possibly decreased risk of UC was associated with the SULT1A1 A/A polymorphism for the heterozygote model (OR=0.86, 95% CI: 0.76-0.98, P=0.471). In the subgroup analysis by cancer type, the results indicated that individuals with the G/G genotype had a significantly higher bladder cancer (BC) risk (GA vs. GG: OR=0.88, 95% CI: 0.74-0.99, P=0.626; GA/AA vs. GG: OR=0.85, 95% CI: 0.74-0.97, P=0.504), which was contrary to the results of the upper urinary tract urothelial carcinoma (UTUC) group (AA vs. GG: OR=2.18, 95% CI: 1.28-3.69; AA vs. GA/GG: OR=2.05, 95% CI: 1.24-3.38). In addition, stratification by smoking status demonstrated that the Arg213His polymorphism was associated with a decreased risk of UC in non-smokers (OR=0.70, 95% CI: 0.53-0.92) but not in smokers (OR=0.85, 95% CI: 0.70-1.03) under the dominant model. In conclusion, this meta-analysis demonstrated a significant association between the SULT1A1 Arg213His polymorphism and BC. However, there was insufficient evidence to support a consistent association between this polymorphism and UC, partly due to the differences between BC and UTUC.

show abstract

Section: Discussionsupporting

confidence: 63%

“…According to the abovementioned inclusion criteria, we identified 10 independent studies (1,8,(16)(17)(18)(19)(20)(21)(22)(23), including a total of 2,495 cases and 2,905 controls (Fig. 1).…”

Section: Resultsmentioning

confidence: 99%

Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma

Liu

Huang

et al. 2014

Molecular and Clinical Oncology

View full text Add to dashboard Cite

show abstract

“…We have recently reported that the variant allele SULT1A1*2, which results in reduced sulfotransferase activity, enhances the risk of UUTTCCs [36]. Sulfation is an important step in the detoxification of many environmental chemicals, but also in the bioactivation of dietary and other mutagens.…”

Section: Somatic Dna Carcinogenesis and Genetic Pathwaysmentioning

confidence: 99%

Anatomical Location of Urothelial Carcinomas of the Urinary Tract Leads To Perspectives of Specific Treatment

Rouprêt

2007

Future Oncol.

View full text Add to dashboard Cite

'The ultimate goal is to relate the tumor genotype with the individual's phenotype and to offer patients treatment that is adapted to the specific molecular pattern of their cancer.'The urothelium is the epithelium that lines the upper and lower urinary tract. Over 95% of urothelial carcinomas are derived from the urothelium [1,2]. They can be located in the lower tract (bladder or urethra) or upper tract (pyelocaliceal cavities or ureter). Urothelial carcinomas are the fourth most common tumors after prostate (or breast) cancer, lung cancer and colorectal cancer. Bladder tumors account for 90-95% of urothelial carcinomas, and it is the most common malignancy of the urinary tract and the second most common malignancy of the urogenital tract after prostate cancer. It accounts for 5-10% of all cancers diagnosed each year in Europe [1,2]. Bladder cancer is ranked the 11th most common cancer in the world and over 50% of cases occur in developed countries [1,2]. Conversely, upper urinary tract transitional cell carcinomas (UUT-TCCs) are scarce and account for only 5-10% of urothelial carcinomas [2,3]. The estimated annual incidence in Western countries is approximately one to two new cases per 100,000 inhabitants.'Bladder cancer is ranked the 11th most common cancer in the world and over 50% of cases occur in developed countries.'Pyelocaliceal tumors are approximately twice as common as ureteral tumors. In 8-13% of cases, a synchronous bladder cancer is present. Recurrence in the bladder or the contralateral urinary tract occurs in 30-51% of UUTTCCs. The natural history of UUT-TCCs differs from that of bladder cancer: 60% of UUTTCCs are invasive at diagnosis compared with only 15% of bladder tumors. Moreover, UUTTCCs invading the muscle wall usually have a very poor prognosis. The 5-year specific survival is less than 50% for pT2/pT3 and less than 10% for pT4 [3,4]. Although the mechanisms of carcinogenesis are thought to be similar throughout the urinary tract, recent epidemiological data and genetic studies suggest otherwise. It is now obvious that strong differences exist with regard to tumor location and behavior between the upper and the lower urinary tract.

show abstract

“…Environmental carcinogens and smoking are the most important etiological factors. Furthermore, the polymorphism reducing the activity of sulfotransferase which triggers the development of UTUC is the only genetic etiological factor described in the literature (4). Histopathologically, these tumors are classified similar to bladder cancers as carcinoma in situ (CIS), lowgrade and high-grade.…”

Section: Introductionmentioning

confidence: 99%

Diagnostic Role of F-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Restaging of Upper Urinary Tract Urothelial Carcinoma

Öztürk¹

2017

jus

View full text Add to dashboard Cite

18FDG-PET/CT was performed for re-staging 6-24 months after nephroureterectomy (mean: 18 months). Nearly 1 hour after intravenous injection of 555 MBq of F-18 FDG, the patients underwent whole-body PET scanning from the skull base to the upper thighs after 6 hours of fasting, and nearly 1 hour after all body CT scanning performed in the craniocaudal direction. By using CT data for attenuation correction, FDG-PET images were reconstructed. Results:18 FDG-PET/CT scans proved negative findings in three patients (17.7%) and positive findings in 14 patients (82.3%). Suspicious recurrent or metastatic lesions were confirmed by histopathology or clinical follow-up. Sensitivity of 18 FDG-PET/CT was 93% and the specificity was 75%. Conclusion:18 FDG-PET/CT defines local recurrence and far metastases with high specificity in re-staging of operated UTUC. It is thought that the procedure could play an important role in decisions regarding radiotherapy or chemotherapy and post-operative follow-up after the operation and could affect the whole decision-making process. Keywords: Upper urinary tract urothelial carcinoma, positron-emission tomography, positron-emission tomography/computed tomography, restaging 18 FDG-PET/BT çalışması nefroüreterektomi sonrası 6-24 ay sonra (ortalama 18 ay) yapıldı. Hastalar taramadan önce 6 saat boyunca aç bırakıldı ve kafa tabanından üst uyluk bölgesine kadar olan alanda F-18 FDG 555 MBq intravenöz enjeksiyonundan yaklaşık 1 saat sonra tüm vücut PET taraması yapıldı. Tüm vücut BT taraması kraniokaudal yönünde yapıldı. FDG-PET imajları doğrulama için BT dataları kullanılarak rekonstrükte edildi. ÖzWhat's known on the subject? and What does the study add?There are quite few data in the literature about re-staging of upper urinary tract urothelial carcinoma with positron-emission tomography/ computed tomography (PET/CT). We may see in the study that PET/CT detects local recurrence and distant metastasis with high specificity.

show abstract

Phenol Sulfotransferase Sult1a1*2 Allele and Enhanced Risk of Upper Urinary Tract Urothelial Cell Carcinoma

Cited by 9 publications

References 0 publications

Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma

Quantitative analysis of the association between sulfotransferase isoform 1A1 polymorphism and risk of urothelial carcinoma

Anatomical Location of Urothelial Carcinomas of the Urinary Tract Leads To Perspectives of Specific Treatment

Diagnostic Role of F-18 Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography in Restaging of Upper Urinary Tract Urothelial Carcinoma

Contact Info

Product

Resources

About